PDCD1 and extranodal nasal NK/T cell lymphoma: Clinical trials showed that the objective remission rate of PD1 antibody monotherapy for R/R NKTCL was 57.1–67.9% and the 2-year overall survival rate was 78.6%.6, 7, 8 Another study showed that the objective remission rate of avelumab (PD-L1 antibody) for R/R NKTCL was 38%, while the complete remission rate was 24%.9